Objective To examine the use of multiple daily injections (MDI), insulin pumps, self-measured blood glucose (SMBG), and continuous glucose monitoring (CGM) systems, and their association with glycated hemoglobin (HbA1c), diabetic ketoacidosis (DKA), and severe hypoglycemia. Methods In a pediatric population-based nationwide cross-sectional study, we analyzed data from 2623 participants up to 18 years of age with type 1 diabetes, using 2017 annual data from the Norwegian Childhood Diabetes Registry. HbA1c was adjusted for age, gender, and diabetes duration. Using a linear mixed-effects model, we assessed HbA1c and the incidence of DKA and severe hypoglycemia according to the use of MDI, insulin pumps, SMBG, and CGM. Results We observed th...
Objective: This study aimed to compare metabolic control measured as hemoglobin A1c (HbA1c), the ris...
Utilisation of technology in the management of youth with type 1 diabetes has increased substantiall...
Aims: To assess glycaemic control in ≥15-year-old patients with type 1 diabetes treated in Tampere U...
Objective To examine the use of multiple daily injections (MDI), insulin pumps, self-measured blood ...
Objective To examine the use of multiple daily injections (MDI), insulin pumps, self-measured blood...
BACKGROUND: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Background: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Background: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Background: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Background: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Aims/hypothesis: While the use of insulin pumps in paediatrics has expanded dramatically, there is...
Background/Aim. The Professional System of Continuous Glucose Monitoring, the iPro®2 CGM System (Med...
Objective: Retrospective continuous glucose monitoring (CGM) can guide insulin pump adjustments, how...
Technologies for diabetes management, such as continuous subcutaneous insulin infusion (CSII) and co...
Objective: This study aimed to compare metabolic control measured as hemoglobin A1c (HbA1c), the ris...
Objective: This study aimed to compare metabolic control measured as hemoglobin A1c (HbA1c), the ris...
Utilisation of technology in the management of youth with type 1 diabetes has increased substantiall...
Aims: To assess glycaemic control in ≥15-year-old patients with type 1 diabetes treated in Tampere U...
Objective To examine the use of multiple daily injections (MDI), insulin pumps, self-measured blood ...
Objective To examine the use of multiple daily injections (MDI), insulin pumps, self-measured blood...
BACKGROUND: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Background: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Background: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Background: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Background: Insulin pumps and real-time continuous glucose monitoring devices have recently been com...
Aims/hypothesis: While the use of insulin pumps in paediatrics has expanded dramatically, there is...
Background/Aim. The Professional System of Continuous Glucose Monitoring, the iPro®2 CGM System (Med...
Objective: Retrospective continuous glucose monitoring (CGM) can guide insulin pump adjustments, how...
Technologies for diabetes management, such as continuous subcutaneous insulin infusion (CSII) and co...
Objective: This study aimed to compare metabolic control measured as hemoglobin A1c (HbA1c), the ris...
Objective: This study aimed to compare metabolic control measured as hemoglobin A1c (HbA1c), the ris...
Utilisation of technology in the management of youth with type 1 diabetes has increased substantiall...
Aims: To assess glycaemic control in ≥15-year-old patients with type 1 diabetes treated in Tampere U...